TOTAL AND UNBOUND DORAVIRINE CONCENTRATIONS AND VIRAL SUPPRESSION IN CSF OF HIV+ PTS
Doravirine (DOR) is a new HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) that has demonstrated a good efficacy and safety profile in clinical trials. Initial pharmacokinetic studies demonstrated a time to maximal concentration of 1–5 h, not extensive binding to plasma proteins (76%) and poor solubility in water. In animal models the tissue distribution was assessed…